ABIGAIL DOYLE: Open Payments
NPI 1164264347 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,723 in 69 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $1,723
Food & beverage: $1,723
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $366 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $226 |
| Madrigal Pharmaceuticals | 7 | $217 |
| GENZYME CORPORATION | 7 | $203 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $156 |
| PFIZER INC. | 7 | $141 |
| Ardelyx, Inc. | 5 | $93 |
| Janssen Biotech, Inc. | 4 | $92 |
| QOL Medical, LLC | 2 | $57 |
| Braintree Laboratories, Inc. | 3 | $54 |
Products named: RINVOQ, XIFAXAN, REZDIFFRA, DUPIXENT, XELJANZ, ENTYVIO, SKYRIZI, IBSRELA.
Industry payments across MA — which companies pay providers there.
